Pharming Group (PHAR) Competitors

$12.60 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$13.03 +0.43 (+3.38%)

As of 05/22/2026 06:26 PM Eastern

PHAR vs. OGN, ACAD, TLX, ORKA, and EWTX

Should you buy Pharming Group stock or one of its competitors? MarketBeat compares Pharming Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pharming Group include Organon & Co. (OGN), ACADIA Pharmaceuticals (ACAD), Telix Pharmaceuticals (TLX), Oruka Therapeutics (ORKA), and Edgewise Therapeutics (EWTX). These companies are all part of the "pharmaceutical products" industry.

How does Pharming Group compare to Organon & Co.?

Organon & Co. (NYSE:OGN) and Pharming Group (NASDAQ:PHAR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Organon & Co. has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market. Comparatively, Pharming Group has a beta of 0.04, suggesting that its share price is 96% less volatile than the broader market.

77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by company insiders. Comparatively, 2.1% of Pharming Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Organon & Co. has a net margin of 3.99% compared to Pharming Group's net margin of 3.30%. Organon & Co.'s return on equity of 99.95% beat Pharming Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.99%	99.95%	6.22%
Pharming Group	3.30%	4.64%	2.55%

Organon & Co. presently has a consensus target price of $11.40, indicating a potential downside of 15.15%. Pharming Group has a consensus target price of $38.33, indicating a potential upside of 204.23%. Given Pharming Group's stronger consensus rating and higher possible upside, analysts clearly believe Pharming Group is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Organon & Co. had 3 more articles in the media than Pharming Group. MarketBeat recorded 4 mentions for Organon & Co. and 1 mentions for Pharming Group. Pharming Group's average media sentiment score of 1.14 beat Organon & Co.'s score of 0.74 indicating that Pharming Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharming Group	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Organon & Co. has higher revenue and earnings than Pharming Group. Organon & Co. is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.45
Pharming Group	$376.13M	2.37	$2.85M	$0.16	78.75

Summary

Organon & Co. beats Pharming Group on 9 of the 16 factors compared between the two stocks.

How does Pharming Group compare to ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Pharming Group (NASDAQ:PHAR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 2.1% of Pharming Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ACADIA Pharmaceuticals has a net margin of 34.30% compared to Pharming Group's net margin of 3.30%. ACADIA Pharmaceuticals' return on equity of 9.61% beat Pharming Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%
Pharming Group	3.30%	4.64%	2.55%

In the previous week, ACADIA Pharmaceuticals and ACADIA Pharmaceuticals both had 1 articles in the media. Pharming Group's average media sentiment score of 1.14 beat ACADIA Pharmaceuticals' score of 0.00 indicating that Pharming Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pharming Group	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ACADIA Pharmaceuticals has higher revenue and earnings than Pharming Group. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	3.37	$391M	$2.20	9.59
Pharming Group	$376.13M	2.37	$2.85M	$0.16	78.75

ACADIA Pharmaceuticals has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, Pharming Group has a beta of 0.04, suggesting that its stock price is 96% less volatile than the broader market.

ACADIA Pharmaceuticals currently has a consensus price target of $31.63, indicating a potential upside of 49.88%. Pharming Group has a consensus price target of $38.33, indicating a potential upside of 204.23%. Given Pharming Group's higher possible upside, analysts clearly believe Pharming Group is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.75
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

ACADIA Pharmaceuticals beats Pharming Group on 13 of the 16 factors compared between the two stocks.

How does Pharming Group compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Pharming Group (NASDAQ:PHAR) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Telix Pharmaceuticals has a beta of 0.08, suggesting that its stock price is 92% less volatile than the broader market. Comparatively, Pharming Group has a beta of 0.04, suggesting that its stock price is 96% less volatile than the broader market.

Pharming Group has a net margin of 3.30% compared to Telix Pharmaceuticals' net margin of 0.00%. Pharming Group's return on equity of 4.64% beat Telix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Pharming Group	3.30%	4.64%	2.55%

0.0% of Pharming Group shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Telix Pharmaceuticals and Telix Pharmaceuticals both had 1 articles in the media. Pharming Group's average media sentiment score of 1.14 beat Telix Pharmaceuticals' score of 0.17 indicating that Pharming Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pharming Group	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pharming Group has lower revenue, but higher earnings than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.00	-$7.12M	N/A	N/A
Pharming Group	$376.13M	2.37	$2.85M	$0.16	78.75

Telix Pharmaceuticals presently has a consensus target price of $21.13, indicating a potential upside of 123.07%. Pharming Group has a consensus target price of $38.33, indicating a potential upside of 204.23%. Given Pharming Group's higher probable upside, analysts plainly believe Pharming Group is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Pharming Group beats Telix Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Pharming Group compare to Oruka Therapeutics?

Pharming Group (NASDAQ:PHAR) and Oruka Therapeutics (NASDAQ:ORKA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Pharming Group has a net margin of 3.30% compared to Oruka Therapeutics' net margin of 0.00%. Pharming Group's return on equity of 4.64% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	3.30%	4.64%	2.55%
Oruka Therapeutics	N/A	-26.16%	-25.00%

In the previous week, Oruka Therapeutics had 14 more articles in the media than Pharming Group. MarketBeat recorded 15 mentions for Oruka Therapeutics and 1 mentions for Pharming Group. Pharming Group's average media sentiment score of 1.14 beat Oruka Therapeutics' score of 0.61 indicating that Pharming Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharming Group	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oruka Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

0.0% of Pharming Group shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 2.1% of Pharming Group shares are held by company insiders. Comparatively, 23.5% of Oruka Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Pharming Group has a beta of 0.04, indicating that its stock price is 96% less volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.2, indicating that its stock price is 120% less volatile than the broader market.

Pharming Group presently has a consensus price target of $38.33, indicating a potential upside of 204.23%. Oruka Therapeutics has a consensus price target of $120.80, indicating a potential upside of 99.31%. Given Pharming Group's higher possible upside, analysts plainly believe Pharming Group is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Pharming Group has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$376.13M	2.37	$2.85M	$0.16	78.75
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A

Summary

Pharming Group beats Oruka Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Pharming Group compare to Edgewise Therapeutics?

Pharming Group (NASDAQ:PHAR) and Edgewise Therapeutics (NASDAQ:EWTX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

Pharming Group has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$376.13M	2.37	$2.85M	$0.16	78.75
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A

0.0% of Pharming Group shares are held by institutional investors. 2.1% of Pharming Group shares are held by insiders. Comparatively, 23.2% of Edgewise Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Pharming Group has a net margin of 3.30% compared to Edgewise Therapeutics' net margin of 0.00%. Pharming Group's return on equity of 4.64% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	3.30%	4.64%	2.55%
Edgewise Therapeutics	N/A	-32.55%	-31.04%

In the previous week, Pharming Group and Pharming Group both had 1 articles in the media. Pharming Group's average media sentiment score of 1.14 beat Edgewise Therapeutics' score of 0.00 indicating that Pharming Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharming Group	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edgewise Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pharming Group currently has a consensus target price of $38.33, indicating a potential upside of 204.23%. Edgewise Therapeutics has a consensus target price of $39.67, indicating a potential upside of 21.30%. Given Pharming Group's higher probable upside, equities analysts plainly believe Pharming Group is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Pharming Group has a beta of 0.04, suggesting that its share price is 96% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market.

Summary

Pharming Group beats Edgewise Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Pharming Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHAR vs. The Competition

Export

Metric	Pharming Group	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$889.88M	$3.37B	$6.45B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	78.75	18.74	21.22	25.65
Price / Sales	2.37	323.98	553.92	86.28
Price / Cash	62.83	125.17	43.49	56.67
Price / Book	3.31	7.09	10.37	7.14
Net Income	$2.85M	$24.45M	$3.57B	$335.98M
7 Day Performance	-0.16%	5.45%	6.01%	3.56%
1 Month Performance	-24.55%	2.43%	3.52%	2.54%
1 Year Performance	20.86%	62.98%	34.13%	35.05%

Pharming Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHAR Pharming Group	3.9848 of 5 stars	$12.60 flat	$38.33 +204.2%	+20.9%	$889.88M	$376.13M	78.75	280	Positive News Gap Up
OGN Organon & Co.	2.9537 of 5 stars	$13.44 +0.1%	$11.40 -15.1%	+54.6%	$3.53B	$6.22B	14.45	10,000
ACAD ACADIA Pharmaceuticals	4.0525 of 5 stars	$20.52 -0.8%	$31.18 +51.9%	-4.0%	$3.51B	$1.07B	9.33	510
TLX Telix Pharmaceuticals	4.6068 of 5 stars	$10.14 -1.3%	$21.13 +108.3%	-43.0%	$3.45B	$803.79M	N/A	1,184
ORKA Oruka Therapeutics	3.6424 of 5 stars	$56.72 -2.8%	$120.80 +113.0%	+453.5%	$3.41B	N/A	N/A	N/A	Insider Trade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHAR) was last updated on 5/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pharming Group (PHAR) Competitors

PHAR vs. OGN, ACAD, TLX, ORKA, and EWTX

How does Pharming Group compare to Organon & Co.?

Summary

How does Pharming Group compare to ACADIA Pharmaceuticals?

Summary

How does Pharming Group compare to Telix Pharmaceuticals?

Summary

How does Pharming Group compare to Oruka Therapeutics?

Summary

How does Pharming Group compare to Edgewise Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAR vs. The Competition

Pharming Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pharming Group (PHAR) Competitors

PHAR vs. OGN, ACAD, TLX, ORKA, and EWTX

How does Pharming Group compare to Organon & Co.?

Which has more risk and volatility, OGN or PHAR?

Do institutionals and insiders hold more shares of OGN or PHAR?

Is OGN or PHAR more profitable?

Do analysts rate OGN or PHAR?

Does the media favor OGN or PHAR?

Which has better earnings & valuation, OGN or PHAR?

Summary

How does Pharming Group compare to ACADIA Pharmaceuticals?

Do institutionals & insiders hold more shares of ACAD or PHAR?

Is ACAD or PHAR more profitable?

Does the media favor ACAD or PHAR?

Which has higher earnings and valuation, ACAD or PHAR?

Which has more risk & volatility, ACAD or PHAR?

Do analysts rate ACAD or PHAR?

Summary

How does Pharming Group compare to Telix Pharmaceuticals?

Which has more volatility & risk, TLX or PHAR?

Is TLX or PHAR more profitable?

Do institutionals and insiders believe in TLX or PHAR?

Does the media favor TLX or PHAR?

Which has preferable valuation and earnings, TLX or PHAR?

Do analysts rate TLX or PHAR?

Summary

How does Pharming Group compare to Oruka Therapeutics?

Is PHAR or ORKA more profitable?

Does the media refer more to PHAR or ORKA?

Do insiders and institutionals believe in PHAR or ORKA?

Which has more risk & volatility, PHAR or ORKA?

Do analysts prefer PHAR or ORKA?

Which has better earnings and valuation, PHAR or ORKA?

Summary

How does Pharming Group compare to Edgewise Therapeutics?

Which has higher valuation and earnings, PHAR or EWTX?

Do institutionals & insiders believe in PHAR or EWTX?

Is PHAR or EWTX more profitable?

Does the media refer more to PHAR or EWTX?

Do analysts prefer PHAR or EWTX?

Which has more risk and volatility, PHAR or EWTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAR vs. The Competition

Pharming Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools